Deregulated NLRP3 and NLRP1 inflammasomes and their correlations with disease activity in systemic lupus erythematosus

Journal of Rheumatology

Volumn 41, Issue 3, 2014, Pages 444-452

  Yang, Qingrui ^a   Yu, Chengcheng ^a   Yang, Zhaowen ^a   Wei, Qing ^a   Mu, Kun ^a   Zhang, Ying ^a   Zhao, Wei ^a   Wang, Xiaofeng ^a   Huai, Wanwan ^a   Han, Lihui ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

AUTOIMMUNE DISEASE; DISEASE ACTIVITY; INFLAMMATION; SYSTEMIC LUPUS ERYTHEMATOSUS

Indexed keywords

CRYOPYRIN; GLUCOCORTICOID; INFLAMMASOME; INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; MYXOVIRUS RESISTANCE 1; MYXOVIRUS RESISTANCE PROTEIN; NOD LIKE RECEPTOR PYRIN DOMAIN CONTAINING 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING;

AUTOIMMUNE DISEASE; DISEASE ACTIVITY; INFLAMMATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; DISEASE PROGRESSION; FEMALE; GLUCOCORTICOIDS; HUMANS; INFLAMMASOMES; LEUKOCYTES, MONONUCLEAR; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84895452992     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130310     Document Type: Article

References (30)

1. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006;24:317-27.
2. Guarda G, Zenger M, Yazdi AS, Schroder K, Ferrero I, Menu P, et al. Differential expression of NLRP3 among hematopoietic cells. J Immunol 2011;186:2529-34.
3. Kummer JA, Broekhuizen R, Everett H, Agostini L, Kuijk L, Martinon F, et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem 2007;55:443-52. (Pubitemid 46668626)
4. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
5. Broz P, von Moltke J, Jones JW, Vance RE, Monack DM. Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe 2010;8:471-83.
6. Elkon KB, Wiedeman A. Type I IFN system in the development and manifestations of SLE. Curr Opin Rheumatol 2012;24:499-505.
7. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692-7. (Pubitemid 41667141)
8. Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol 2011;23:113-21.
9. Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res 2011;31:887-92.
10. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007;56:3759-69. (Pubitemid 350100709)
11. Li D, Song L, Fan Y, Li X, Li Y, Chen J, et al. Down-regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol 2009;133:422-7.
12. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62. (Pubitemid 44497776)
13. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-16. (Pubitemid 43877940)
14. Pontillo A, Girardelli M, Kamada AJ, Pancotto JA, Donadi EA, Crovella S, et al. Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 2012;45:271-8.
15. Shaw PJ, McDermott MF, Kanneganti TD. Inflammasomes and autoimmunity. Trends Mol Med 2011;17:57-64.
16. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010;207:1045-56.
17. Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2011;17:1359-72.
18. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010;32:379-91.
19. Zaki MH, Lamkanfi M, Kanneganti TD. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol 2011;32:171-9.
20. Lamkanfi M, Dixit VM. Inflammasomes: guardians of cytosolic sanctity. Immunol Rev 2009;227:95-105.
21. Guarda G, Dostert C, Staehli F, Cabalzar K, Castillo R, Tardivel A, et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 2009;460:269-73.
22. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011;34:213-23.
23. Inoue M, Williams KL, Oliver T, Vandenabeele P, Rajan JV, Miao EA, et al. Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal 2012;5:ra38.
24. Veeranki S, Duan X, Panchanathan R, Liu H, Choubey D. IFI16 protein mediates the anti-inflammatory actions of the type-I interferons through suppression of activation of caspase-1 by inflammasomes. PLoS One 2011;6:e27040.
25. Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol 2012;13:333-2.
26. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-32.
27. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012;481:278-86.
28. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009;10:241-7.
29. Gray DH, Kupresanin F, Berzins SP, Herold MJ, O'Reilly LA, Bouillet P, et al. The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens. Immunity 2012;37:451-62.
30. Zhang J, Xu X, Liu Y. Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol 2004;1:186-92.